Controlled trial of sodium valproate in severe epilepsy.
- 1 November 1975
- Vol. 4 (5991) , 255-256
- https://doi.org/10.1136/bmj.4.5991.255
Abstract
In a double-blind crossover trial sodium valproate or placebo was added to the existing anticonvulsant treatment of 20 patients with chronic uncontrolled epilepsy. Sodium valproate 1200 mg/day significantly reduced the frequency of both tonic-clonic and minor seizures in these patients. Only mild and transient side effects occurred (drowsiness, ataxia, and nausea), and these may have been due to the effect of adding sodium valproate to existing phenobarbitone or phenytoin treatment. Further controlled trials are needed to assess more fully the efficacy of this drug in various types of epilepsy.Keywords
This publication has 6 references indexed in Scilit:
- Pharmacokinetics of di-n-propylacetate in epileptic patientsEuropean Journal of Clinical Pharmacology, 1975
- Sodium Valproate in Treatment of EpilepsyBMJ, 1974
- [Treatment of refractory epilepsy with dipropyl acetate].1973
- Dipropylacetate (Depakine®, Ergenyl®) in the Treatment of EpilepsyEpilepsia, 1973
- Clinical trials of anti-epileptic drugs.1971
- [Pharmacodynamic properties of N-dipropylacetic acid].1963